



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

Rs. in Lakhs

Sl. No.	Particulars	3 Months ended September 30, 2019	Preceding 3 Months ended June 30, 2019	Corresponding 3 Months ended in the previous year September 30, 2018	Year to date figures for the current period ended September 30, 2019	Year to date figures for the previous period ended September 30, 2018	Previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
	Continuing operations						
I	Revenue from operations	71,509	68,580	51,961	140,089	99,230	217,837
II	Other income	1,299	1,025	985	2,324	1,461	4,084
III	Total income (I + II)	72,808	69,605	52,946	142,413	100,691	221,921
IV	Expenses						
	(a) Cost of materials consumed	25,799	30,916	26,003	56,715	53,616	100,205
	(b) Purchases of stock-in-trade	3,354	3,823	5,369	7,177	6,119	18,715
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	737	(3,154)	(5,392)	(2,417)	(8,089)	(10,400)
	(d) Employee benefits expense	10,970	9,713	9,071	20,683	16,809	32,944
	(e) Finance costs (Refer note 3)	4,042	3,534	1,728	7,576	3,403	7,929
	(f) Depreciation and amortisation expense (Refer note 3)	4,200	4,289	3,086	8,489	5,987	11,739
	(g) Other expenses (Refer note 3)	15,990	14,921	12,075	30,911	21,660	50,807
	(h) Foreign exchange (gain) / loss - net	(108)	269	437	161	266	1,335
	Total expenses (IV)	64,984	64,311	52,377	129,295	99,771	213,274
V	Profit before exceptional items and tax (III - IV)	7,824	5,294	569	13,118	920	8,647
VI	Exceptional items - net gain / (loss) (Refer note 8)	8,344	(665)	(499)	7,679	(794)	2,162
VII	(Loss) / Profit before tax (V + VI)	16,168	4,629	70	20,797	126	10,809
VIII	Share of profit / (loss) of joint ventures and associates	(2,125)	(1,781)	(1,154)	(3,906)	(1,851)	(4,570)
IX	(Loss) / Profit before tax (VII + VIII)	14,043	2,848	(1,084)	16,891	(1,725)	6,239
X	Tax expense						
	- Current tax	1,608	1,550	171	3,158	350	2,892
	- Deferred tax	(870)	(1,238)	(725)	(2,108)	(2,257)	(5,578)
	Total tax expense (X)	738	312	(554)	1,050	(1,907)	(2,686)
XI	(Loss) / Profit after tax from continuing operations (IX - X)	13,305	2,536	(530)	15,841	182	8,925
XII	Discontinued operations						
	- Profit / (Loss) from discontinued operations	(256)	(1,586)	551	(1,842)	350	966
	- Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	1,142	-	(203)	1,142	(204)	27,231
	- Tax expense / (benefit) of discontinued operations	-	659	688	659	1,454	4,135
XIII	Profit/(loss) after tax from discontinued operations	886	(2,245)	(340)	(1,359)	(1,308)	24,062
XIV	Profit/(loss) for the period (XI + XIII)	14,191	291	(870)	14,482	(1,126)	32,987



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

Rs. in Lakhs

Sl. No.	Particulars	3 Months ended September 30, 2019	Preceding 3 Months ended June 30, 2019	Corresponding 3 Months ended in the previous year September 30, 2018	Year to date figures for the current period ended September 30, 2019	Year to date figures for the previous period ended September 30, 2018	Previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
XV	Other comprehensive income						
A	(i) Items that will not be reclassified to statement of profit and loss	(83)	(801)	231	(884)	228	(12)
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	-	-	-	-	5	43
B	(i) Items that may be reclassified to statement of profit and loss	3,642	(3,058)	350	584	(2,672)	(6,200)
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	136	77	696	213	1,489	(190)
	Total other comprehensive income for the period (XV)	3,695	(3,782)	1,277	(87)	(950)	(6,359)
XVI	Total comprehensive income for the period (XIV + XV)	17,886	(3,491)	407	14,395	(2,076)	26,628
	Profit for the period attributable to:						
	- Owners of the Company	14,272	370	(1,201)	14,642	(1,632)	32,461
	- Non-controlling interests	(81)	(79)	331	(160)	506	526
		14,191	291	(870)	14,482	(1,126)	32,987
	Other comprehensive income for the period						
	- Owners of the Company	3,689	(3,705)	1,020	(16)	(1,338)	(6,342)
	- Non-controlling interests	6	(77)	257	(71)	388	(17)
		3,695	(3,782)	1,277	(87)	(950)	(6,359)
	Total comprehensive income for the period						
	- Owners of the Company	17,961	(3,335)	(181)	14,626	(2,970)	26,119
	- Non-controlling interests	(75)	(156)	588	(231)	894	509
		17,886	(3,491)	407	14,395	(2,076)	26,628
	Earnings per equity share (face value of Rs. 10/- each) (for continuing operations)						
	(1) Basic (in Rs.)	14.95	3.11	(0.52)	18.06	0.38	10.71
	(2) Diluted (in Rs.)	14.95	3.11	(0.52)	18.06	0.38	10.71
	Earnings per equity share (face value of Rs. 10/- each) (for discontinued operations)						
	(1) Basic (in Rs.)	0.99	(2.70)	(0.82)	(1.71)	(2.20)	25.54
	(2) Diluted (in Rs.)	0.99	(2.70)	(0.82)	(1.71)	(2.20)	25.53
	Earnings per equity share (face value of Rs. 10/- each) (for total operations)						
	(1) Basic (in Rs.)	15.94	0.41	(1.34)	16.35	(1.82)	36.25
	(2) Diluted (in Rs.)	15.94	0.41	(1.34)	16.35	(1.82)	36.24
	See accompanying notes to the Financial Results						



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

CONSOLIDATED BALANCE SHEET

Particulars		Rs in Lakhs	
		As at September 30, 2019	As at March 31, 2019
		UNAUDITED	AUDITED
A	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	103,796	103,742
	(b) Capital work-in-progress	12,064	10,200
	(c) Right-of-use assets (Refer note 3)	21,442	-
	(d) Investment property	7,507	7,737
	(e) Goodwill	39,348	136,911
	(f) Other Intangible assets	22,902	116,066
	(g) Intangibles assets under development	34,376	40,400
	(h) Investment in associates and joint ventures	41,506	40,578
	(i) Financial assets		
	(i) Investments	234	1,119
	(ii) Loans receivable	3,142	6,827
	(iii) Other financial assets	43,135	234
	(j) Deferred tax assets (net)	17,278	15,217
	(k) Income tax assets (net)	12,034	13,626
	(l) Other non-current assets	3,268	3,367
	Total non-current assets	362,032	496,024
II	Current assets		
	(a) Inventories	71,995	87,070
	(b) Financial assets		
	(i) Investments	14,112	28,475
	(ii) Trade receivables	100,021	98,718
	(iii) Cash and cash equivalents	17,734	36,589
	(iv) Other balances with banks	7,878	15,076
	(v) Loans receivable	320	5,415
	(vi) Other financial assets	1,644	8,067
	(c) Other current assets	23,075	25,116
	Total current assets	236,779	304,526
	Total Assets	598,811	800,550



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

Particulars		Rs in Lakhs	
		As at September 30, 2019	As at March 31, 2019
		UNAUDITED	AUDITED
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	8,955	8,955
	(b) Other equity	250,835	255,916
	Equity attributable to owners of the Company	259,790	264,871
	Non- Controlling interests	6,991	15,296
	Total equity	266,781	280,167
II	Liabilities		
1	Non-current liabilities		
	(a) Financials liabilities		
	(i) Lease liabilities (Refer note 3)	22,404	5
	(ii) Borrowings	57,931	180,651
	(iii) Other financial liabilities	9,671	45,653
	(b) Provisions	2,401	2,152
	(c) Deferred tax liabilities (net)	3,134	20,560
	(d) Other non-current liabilities	139	1,037
	Total non-current liabilities	95,680	250,058
2	Current liabilities		
	(a) Financials liabilities		
	(i) Lease liabilities (Refer note 3)	1,782	229
	(ii) Borrowings	122,238	133,902
	iii) Trade payables		
	(a) total outstanding dues of micro enterprises and small enterprises	768	574
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	70,140	88,843
	(iv) Other financial liabilities	15,571	17,150
	(b) Provisions	14,345	16,201
	(c) Current tax liabilities	5,730	5,828
	(d) Other current liabilities	5,776	7,598
	Total current liabilities	236,350	270,325
	Total Equity and liabilities	598,811	800,550



STRIDES PHARMA SCIENCE LIMITED
 Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

CONSOLIDATED STATEMENT OF CASH FLOW

Sl. No.	Particulars	Rs. In Lakhs		
		For the current period ended September 30, 2019	For the previous period ended September 30, 2018	For the previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	AUDITED
A.	Cash flow from operating activities			
	Profit before tax from:			
	Continuing operations	16,891	(1,725)	6,239
	Discontinued operations	(700)	146	28,197
		16,191	(1,579)	34,436
	Adjustments for:			
	- Depreciation and amortisation expense	9,898	8,736	17,185
	- Share of profit / (loss) of joint ventures and associates	3,956	2,021	4,832
	- (Profit)/ loss on sale of property, plant and equipment and other intangible assets (net)	98	(67)	(113)
	- Share based compensation expense	140	282	90
	- Unwinding of discount on gross obligations over written put options to NCI	196	456	278
	- Unwinding of discount on contingent consideration payable	504	17	426
	- Cancellation of gross obligations over written put options to NCI	(10,929)	-	-
	- Interest expense on borrowings & others	10,769	9,260	20,534
	- Interest and dividend income	(1,868)	(832)	(3,071)
	- Rental income from investment property	(373)	(576)	(947)
	- Bad debts written off / provision for doubtful trade and other receivables	209	(86)	579
	- Impairment of goodwill	949	-	3,700
	- Restructuring and divestment related expenses	996	186	1,832
	- Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	(1,142)	204	(27,231)
	- Loss on sale of investment in subsidiaries	-	144	144
	- Fair valuation of derivative instruments	-	(665)	(661)
	- Fair valuation on investment in associates	-	-	(5,879)
	- Fair valuation gain on acquisition of controlling shares in Vivimed Life Sciences India Private Limited	-	-	(2,704)
	- Net unrealised exchange loss/ (gain)	1,427	551	468
	Operating profit before working capital changes	31,021	18,052	43,898
	Changes in working capital:			
	(Increase) / decrease in trade and other receivables	(17,945)	(9,717)	(17,248)
	Decrease / (increase) in inventories	(1,732)	(22,787)	(30,555)
	(Decrease)/ Increase in trade and other payables	(2,823)	10,071	15,485
	Net change in working capital	(22,500)	(22,433)	(32,318)
	Cash generated from operations	8,521	(4,381)	11,580
	Income taxes paid	(1,330)	(1,385)	(5,576)
	Net cash flow generated from operating activities	7,191	(5,766)	6,004
	A			



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.
 STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

Sl. No.	Particulars	Rs. In Lakhs		
		For the current period ended September 30, 2019	For the previous period ended September 30, 2018	For the previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	AUDITED
B.	Cash flow from investing activities			
	Capital expenditure for property, plant and equipment and intangible assets, including capital advance	(9,470)	(8,221)	(32,908)
	Proceeds from sale of property, plant and equipment and intangible assets	62	656	1,267
	Short-term investments in funds	-	(5,040)	(13,046)
	Purchase of long-term investments including investment in associates	(6,103)	-	(7,500)
	Consideration paid towards business combinations, net of cash acquired	-	(900)	(7,005)
	Consideration paid towards acquisition of non-controlling interest in subsidiary	(1,816)	-	-
	Proceeds from sale of investment in mutual funds	14,777	10,229	15,854
	Proceeds from sale of long-term investments including discontinued operations, net of expenses and cash	129,192	3,966	42,698
	Loan (given) to others	(894)	(4,000)	(5,397)
	Loan recovered from others	2,500	-	-
	Rent deposit received / (given)	(121)	(103)	1
	Proceeds / (investment) in fixed deposits with maturity of more than 3 months, net	6,515	1,586	(10,237)
	Rental income from investment property	387	589	979
	Cash earmarked for dividend payout	-	(1,791)	-
	Interest and dividends received (net of tax on dividend)	813	375	446
	Net cash flow generated from / (utilised) in investing activities	B	(2,654)	(14,848)
C.	Cash flow from financing activities			
	Proceeds from issue of equity shares	6	139	140
	Proceeds from long-term borrowings	1,633	12,302	20,512
	Repayment of long-term borrowings	(133,877)	(1,322)	(3,023)
	Net (decrease) / increase in working capital and short-term borrowings	(2,989)	4,813	23,272
	Lease payments	(547)	-	-
	Dividends paid (net of tax on dividend)	(15,389)	-	(1,795)
	Proceeds from issue of shares to minority shareholders	2	327	327
	Dividend paid to minority shareholders	(95)	-	(60)
	Interest paid on borrowings	(10,237)	(9,717)	(19,946)
	Net cash utilised in financing activities	C	6,542	19,427



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.
 STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

Sl. No.	Particulars	Rs. In Lakhs		
		For the current period ended September 30, 2019	For the pervious period ended September 30, 2018	For the previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	AUDITED
	Net (decrease) / increase in cash and cash equivalents during the year	(18,460)	(1,878)	10,583
	Cash and cash equivalents at the beginning of the year	36,589	25,616	25,616
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(395)	1,986	390
	Cash and cash equivalents at the end of the year	17,734	25,724	36,589
	* Comprises:			
	Cash on hand	25	37	27
	Balance with banks:			
	- In current accounts	13,444	23,610	32,263
	- In Escrow accounts	-	20	20
	- In deposit accounts	2,700	392	506
	- Funds-in-transit	1,565	1,665	3,773
	Total	17,734	25,724	36,589



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

Notes:

- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 25, 2019. The statutory auditors have reviewed the results for the quarter and half year ended September 30, 2019 and have issued an unmodified opinion.
- Effective April 1, 2019, the Group adopted Ind AS 116 'Leases', applied to all lease contracts existing on April 1, 2019 using the modified retrospective method and has taken the cumulative adjustment to retained earnings, on the date of initial application. Accordingly, comparatives for the year ended March 31, 2019 have not been restated. The effect of this adoption has resulted in recognition of Right-of-use assets (ROU) amounting to Rs.16,214 Lakhs and lease liability of Rs. 19,202 lakhs, resulting to a debit of Rs. 2,664 Lakhs (net of taxes) to retained earnings. Further, it has also resulted in decrease in other expenses of Rs. 1,340 lakhs, increase in interest expenses (included under finance cost) of Rs.707 Lakhs and an increase in depreciation and amortisation expenses of Rs. 845 lakhs, resulting in a reduction in profit for the half year ended September 30, 2019 by Rs.212 lakhs.
- During the previous year, the Board of Directors had proposed to divest the Group's equity interest in the Australia business to Dennis Bastas- Executive Chairman of Arrow Pharmaceuticals Pty Limited, Australia (Arrow). Further, the group had obtained the approval from the Company's shareholders' in the EGM held on March 27, 2019.

On July 10, 2019, the Group completed the divestment of its Australia business for a consideration of AUD 406 Million (including a deferred consideration of AUD 106 Million) reduced by the bank debt settlement of AUD 22.47 Million. Additionally, the Group has retained global access to IP's of over 140 products and has concurrently entered into a preferred supply agreement with Arotex. The resulting gain from the disposal of Rs.1,142 lakhs is accounted under the head "Gain on disposal of assets attributable to the discontinued operations (net)" and is presented as part of discontinued operations.

Accordingly, the Group has classified the Australia business operations as discontinued operations. The results of discontinued operations (including discontinued operations of earlier periods) are disclosed in the table below:

Sl. No.	Particulars	Rs. in Lakhs					
		3 Months ended September 30, 2019	Preceding 3 Months ended June 30, 2019	Corresponding 3 Months ended in the previous year September 30, 2018	Year to date figures for the current period ended September 30, 2019	Year to date figures for the previous period ended September 30, 2018	Previous year ended March 31, 2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Total Revenue	-	23,050	23,107	23,050	44,612	93,501
II	Total Expenses	256	23,454	22,241	23,710	43,653	89,849
III	Profit/(loss) before exceptional items and tax (I - II)	(256)	(404)	866	(660)	959	3,652
IV	Exceptional items	-	(1,132)	(239)	(1,132)	(439)	(2,424)
V	Profit/(loss) before tax (III + IV)	(256)	(1,536)	627	(1,792)	520	1,228
VI	Share of profit / (loss) of joint ventures and associates	-	(50)	(76)	(50)	(170)	(262)
VII	Profit/(loss) before tax (V + VI)	(256)	(1,586)	551	(1,842)	350	966
VIII	Gain / (loss) on disposals (net)	1,142	-	(203)	1,142	(204)	27,231
IX	Tax expense / (benefit)	-	659	688	659	1,454	4,135
X	Profit/(loss) from discontinued operations (VII+ VIII - IX)	886	(2,245)	(340)	(1,359)	(1,308)	24,062

- During the current quarter, the group through its subsidiary Strides Pharma Global Pte Limited, Singapore invested in 70% equity interest in Fair-med Healthcare AG, Switzerland.
- During the current quarter, the group through its subsidiary Strides Pharma Inc., USA acquired USFDA approved manufacturing facility in Florida, USA for a cash consideration of USD 5 lakhs.
- The Group's operations for the current and previous year relate only to the "Pharmaceutical business" and accordingly no separate disclosure for business segments is being provided.



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019**

8 Exceptional Item gain/ (loss) (net):

Particulars	Rs. in Lakhs						
	3 Months ended September 30, 2019	Preceding 3 Months ended June 30, 2019	Corresponding 3 Months ended in the previous year September 30, 2018	Year to date figures for the current period ended September 30, 2019	Year to date figures for the previous period ended September 30, 2018	Previous year ended March 31, 2019	
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
- Exchange gain/ (loss) on long-term foreign currency loans, derivatives and intra-group loans	(1,183)	(224)	(195)	(1,407)	(408)	(680)	
- Impairment of Goodwill	(949)	-	-	(949)	-	(3,700)	
- Fair valuation of investment	-	-	-	-	-	5,879	
- Fair valuation gain on acquisition of controlling shares in VLSPL	-	-	-	-	-	2,704	
- Business combination and restructuring expenses	(159)	(172)	(74)	(331)	(101)	(1,214)	
-Unwinding/ cancellation of gross obligations and contingent consideration(Refer note below)	10,635	(269)	(86)	10,366	(141)	(683)	
- Fair valuation of derivative instruments	-	-	-	-	-	-	
- Loss on sale of Investment in subsidiaries	-	-	(144)	-	(144)	(144)	
Total	8,344	(665)	(499)	7,679	(794)	2,162	

During the current quarter, the Group has cancelled the obligation under the put option to acquire non-controlling interest (49%) of Universal Corporation Limited, Kenya. Consequently, the gross obligation liability accrued at the time of acquisition under the aforesaid put option(including subsequent unwinding) amounting to Rs. 10,929 lakhs has been reversed to the Statement of Profit and Loss under exceptional items.

9 Information on Standalone Results :-

Particulars	Rs. in Lakhs						
	3 Months ended September 30, 2019	Preceding 3 Months ended June 30, 2019	Corresponding 3 Months ended in the previous year September 30, 2018	Year to date figures for the current period ended September 30, 2019	Year to date figures for the previous period ended September 30, 2018	Previous year ended March 31, 2019	
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
Total Revenue from continuing operations	45,761	46,561	35,879	92,322	72,433	165,205	
Profit/(loss) before tax from continuing operations	5,822	3,034	(1,159)	8,856	33	11,303	
Profit/(loss) after tax from continuing operations	4,700	2,468	(1,027)	7,168	28	11,441	
Profit/(loss) before tax from discontinued operations	-	-	(469)	-	(470)	(470)	
Profit/(loss) after tax from discontinued operations	-	-	(403)	-	(404)	(404)	

10 During the previous year, on July 2, 2018 and July 18, 2018, the Company received shareholders' approval and approval from Registrar of Companies, respectively, for change of name to Strides Pharma Science Limited.

11 The Board of Directors at its meeting held on July 29, 2019 approved an interim dividend of Rs 12 per equity share and which was paid during the quarter.

12 Previous period figures have been regrouped to conform with the classification adopted in these financial results.

For and on behalf of the Board

Arun Kumar
Group CEO & Managing Director

Bengaluru, October 25, 2019